GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ALTO-100 overview
ALTO-100 is under development for the treatment of post-traumatic stress disorder (PTSD) and major depressive disorder (MDD). ALTO-100 is administered through oral route. It acts by targeting BDNF
Alto Neuroscience overview
Alto Neuroscience is a biopharmaceutical company that develops drugs for psychiatric and mental health conditions. It is investigating ALTO-100, ALTO-202, and ALTO-300 drugs for the treatment of major depressive disorder (MDD) and post-traumatic stress disorder (PTSD) by targeting cognition, emotion and sleep systems. The company utilizes its AI-enabled drug development platform that identifies biomarkers by evaluating brain function measures to develop its product candidates. Alto Neuroscience is headquartered in Los Altos, California, the US.
For a complete picture of ALTO-100’s drug-specific PTSR and LoA scores, buy the report here.
From 
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.